Stanford researchers have demonstrated the application of pulsed Focused Ultrasound (pFUS), to non-invasively enhance the function and engraftment of pancreatic islets following transplantation.
Researchers at Stanford have developed agents to enhance the therapeutic efficacy of a variety of anti-cancer therapeutics. Cell loss by apoptosis occurs in normal development and in tumor environments.
Researchers in Dr. Mark Kay's lab have developed a patented approach to inducing apoptosis that could represent a new strategy against cancer and other diseases.
Researchers at Stanford have developed a device capable of delivering ultrasonic neuromodulation to defined areas of the brain while simultaneously recording neuronal activity with cell-type specificity.
Stanford researchers have proposed the use of a conductive graphene scaffold (CGS) as a biocompatible scaffold for growth of neural tissues. The high conductivity enables the use of electrical stimulation to control the development of induced pluripotent stem cells (iPSCs).
Researchers at Stanford and their colleagues have developed new antibiotic compounds that could be used to treat staph infection (caused by Staphylococcus aureus) and TB infection (caused by Mycobacterium tuberculosis).
A team of Stanford scientists have developed a technique to rapidly convert adult somatic cells directly into functional neuronal cells without the intermediate step of generating iPS cells (induced pluripotent stem cells).
Stanford researchers have developed a gene therapy that combines a retinal ganglion cell (RGC)- specific promoter with CRISPR gene editing to provide effective neuroprotection in optic neuropathies.
Stanford researchers have designed a frequency-multiplexed neural probe architecture that enables massive scaling of electrophysiological recording from neurons.
Stanford researchers have designed a non-invasive, low power ultrasonic neuromodulation device which can target tissue deep in the brain with high spatial-temporal resolution.
Researchers at Stanford have developed chimeric antigen receptors (CARs) that target glypican-2 (GPC2) and can be used to treat solid tumors. CAR-engineered T cells have shown great promise as cancer therapeutics.
Researchers at Stanford have developed a combination therapy to treat neuroblastoma, the most common and deadly solid tumor in childhood. Neuroblastoma derives from neural crest cells that fail to exit the cell cycle and differentiate.